Effectiveness of oxaliplatin desensitization protocols

被引:23
作者
Cortijo-Cascajares, Susana [1 ]
Nacle-Lopez, Inmaculada [2 ]
Garcia-Escobar, Ignacio [3 ]
Jose Aguilella-Vizcaino, Maria [1 ]
Herreros-de-Tejada, Alberto [1 ]
Cortes-Funes Castro, Hernan [3 ]
Calleja-Hernandez, Miguel-Angel [4 ]
机构
[1] Hosp Univ 12 Octubre, Dept Pharm, Madrid 28041, Spain
[2] Hosp San Juan de la Cruz, Dept Pharm, Jaen, Spain
[3] Hosp Univ 12 Octubre, Dept Oncol, Madrid 28041, Spain
[4] Hosp Virgen de las Nieves, Dept Pharm, Granada, Spain
关键词
Oxaliplatin; Desensitization; Hypersensitivity reactions; HYPERSENSITIVITY REACTIONS; IDIOSYNCRATIC REACTIONS; RAPID DESENSITIZATION; RISK-FACTORS; CHEMOTHERAPY; MANAGEMENT; DIAGNOSIS; SYMPTOMS; RELEASE;
D O I
10.1007/s12094-012-0909-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypersensitivity reaction (HSR) to antineoplastic drugs can force doctors to stop treatment and seek other alternatives. These alternatives may be less effective, not as well tolerated and/or more expensive. Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached. The aim of this study is to assess the effectiveness of oxaliplatin desensitization protocols. A retrospective observational study was carried out between January 2006 and May 2011. The inclusion criteria were patients undergoing chemotherapy treatment with oxaliplatin who had developed an HSR to the drug and who were candidates for continuing the treatment using a desensitization protocol. The patients' clinical records were reviewed and variables were gathered relating to the patient, the treatment, the HSR, and the desensitization protocol administered. The data were analysed using version 18.0 of the statistics program SPSS. A total of 53 desensitization protocols were administered to 21 patients. In 89 % of these cases, no new reactions occurred while the drug was being administered. New reactions of mild severity only occurred in 11 % of cases, and none of these reactions were severe enough for treatment to be stopped. All patients were able to complete the desensitization protocol. This study confirms that oxaliplatin desensitization protocols are safe and effective and allow patients to continue with the treatment that initially caused an HSR.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 32 条
  • [1] Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Bhargava, P
    Gammon, D
    McCormick, MJ
    [J]. CANCER, 2004, 100 (01) : 211 - 212
  • [2] Hypersensitivity reactions related to oxaliplatin (OHP)
    Brandi, G
    Pantaleo, MA
    Galli, C
    Falcone, A
    Antonuzzo, A
    Mordenti, P
    Di Marco, MC
    Biasco, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 477 - 481
  • [3] Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
    Castells, Mariana C.
    Tennant, Nichole M.
    Sloane, David E.
    Hsu, F. Ida
    Barrett, Nora A.
    Hong, David I.
    Laidlaw, Tanya M.
    Legere, Henry J.
    Nallamshetty, Samridhi N.
    Palis, Ross I.
    Rao, Jayanti J.
    Berlin, Suzanne T.
    Campos, Susana M.
    Matulonis, Ursula A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (03) : 574 - 580
  • [4] Serious delayed hypersensitivity reaction to oxaliplatin
    de Vries, R. S.
    Mattijssen, E. J.
    van Sorge, A. A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (11)
  • [5] Edmondson David A, 2007, Am J Ther, V14, P116, DOI 10.1097/01.pap.0000249924.90645.5b
  • [6] Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol
    Gammon, D
    Bhargava, P
    McCormick, MJ
    [J]. ONCOLOGIST, 2004, 9 (05) : 546 - 549
  • [7] Skin testing and hypersensitivity reactions to oxaliplatin
    Garufi, C
    Cristaudo, A
    Vanni, B
    Bria, E
    Aschelter, AM
    Santucci, B
    Terzoli, E
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (03) : 497 - 498
  • [8] Gastaminza G, 2011, J INVEST ALLERG CLIN, V21, P108
  • [9] Gottlieb GR., 2010, COMMUNITY ONCOL, V7, P452, DOI [10.1016/S1548-5315(11)70425-9, DOI 10.1016/S1548-5315(11)70425-9]
  • [10] Habert H, 2009, PHARM WORLD SCI, V31, P96